4//SEC Filing
Voliotis Dimitris 4
Accession 0001725160-22-000015
CIK 0001725160other
Filed
Jan 19, 7:00 PM ET
Accepted
Jan 20, 7:15 PM ET
Size
30.8 KB
Accession
0001725160-22-000015
Insider Transaction Report
Form 4
Voliotis Dimitris
SVP, Clinical Development
Transactions
- Sale
Common Stock
2022-01-18$61.70/sh−3,409$210,326→ 12,841 total - Sale
Common Stock
2022-01-20$61.21/sh−1,657$101,419→ 6,250 total - Sale
Common Stock
2022-01-18$63.48/sh−1,997$126,767→ 7,550 total - Exercise/Conversion
Common Stock
2022-01-20$18.00/sh+10,000$180,000→ 16,250 total - Exercise/Conversion
Common Stock
2022-01-18$18.00/sh+10,000$180,000→ 16,250 total - Sale
Common Stock
2022-01-18$64.66/sh−1,300$84,064→ 6,250 total - Exercise/Conversion
Common Stock
2022-01-19$18.00/sh+10,000$180,000→ 16,250 total - Sale
Common Stock
2022-01-19$60.55/sh−7,889$477,683→ 8,361 total - Sale
Common Stock
2022-01-19$61.51/sh−1,556$95,707→ 6,805 total - Sale
Common Stock
2022-01-20$60.52/sh−8,343$504,904→ 7,907 total - Exercise/Conversion
Stock Option
2022-01-18−10,000→ 144,949 totalExercise: $18.00Exp: 2030-03-25→ Common Stock (10,000 underlying) - Exercise/Conversion
Stock Option
2022-01-20−10,000→ 124,949 totalExercise: $18.00Exp: 2030-03-25→ Common Stock (10,000 underlying) - Sale
Common Stock
2022-01-18$62.34/sh−3,294$205,334→ 9,547 total - Sale
Common Stock
2022-01-19$62.24/sh−555$34,541→ 6,250 total - Exercise/Conversion
Stock Option
2022-01-19−10,000→ 134,949 totalExercise: $18.00Exp: 2030-03-25→ Common Stock (10,000 underlying)
Footnotes (11)
- [F1]The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2021.
- [F10]The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $61.01 to $61.61. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F11]The option vests and becomes exercisable as to 25% of the shares on March 25, 2021 and vests in equal monthly installments thereafter until March 25, 2024.
- [F2]The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $60.97 to $61.96. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $61.98 to $62.93. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $63.18 to $64.02. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F5]The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $64.23 to $65.19. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F6]The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $60.07 to $61.05. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F7]The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $61.09 to $61.94. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F8]The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $62.15 to $62.41. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F9]The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $60.00 to $60.95. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Documents
Issuer
Zentalis Pharmaceuticals, Inc.
CIK 0001725160
Entity typeother
Related Parties
1- filerCIK 0001807910
Filing Metadata
- Form type
- 4
- Filed
- Jan 19, 7:00 PM ET
- Accepted
- Jan 20, 7:15 PM ET
- Size
- 30.8 KB